Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SMMT
Previous Symbol
CUSIPN/A
Phone44-0-12-3544-3939
Debt
Debt-to-Equity RatioN/A
Current Ratio1.83
Quick Ratio1.83
Price-To-Earnings
Trailing P/E Ratio-1.72
Forward P/E Ratio1.33
P/E GrowthN/A
Sales & Book Value
Annual Sales$36.07 million
Price / Sales0.49
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.93 per share
Price / Book1.38
Profitability
EPS (Most Recent Fiscal Year)($0.75)
Net Income$-9,280,000.00
Net Margins13.38%
Return on Equity58.72%
Return on Assets11.13%
Miscellaneous
Employees60
Outstanding Shares13,840,000
Market Cap$16.89 million
OptionableOptionable
SUMMIT THERAPEU/S (NASDAQ:SMMT) Frequently Asked Questions
What is SUMMIT THERAPEU/S's stock symbol?
SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT."
How were SUMMIT THERAPEU/S's earnings last quarter?
SUMMIT THERAPEU/S (NASDAQ:SMMT) issued its quarterly earnings results on Thursday, September, 20th. The company reported $2.10 EPS for the quarter, beating the consensus estimate of ($0.74) by $2.84. The company had revenue of $49.82 million for the quarter. SUMMIT THERAPEU/S had a net margin of 13.38% and a return on equity of 58.72%. View SUMMIT THERAPEU/S's Earnings History.
When is SUMMIT THERAPEU/S's next earnings date?
What price target have analysts set for SMMT?
9 equities research analysts have issued 12 month price objectives for SUMMIT THERAPEU/S's stock. Their forecasts range from $3.00 to $33.00. On average, they anticipate SUMMIT THERAPEU/S's stock price to reach $14.7143 in the next twelve months. This suggests a possible upside of 1,049.6% from the stock's current price. View Analyst Price Targets for SUMMIT THERAPEU/S.
What is the consensus analysts' recommendation for SUMMIT THERAPEU/S?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SUMMIT THERAPEU/S in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SUMMIT THERAPEU/S.
Has SUMMIT THERAPEU/S been receiving favorable news coverage?
News stories about SMMT stock have been trending positive on Wednesday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. SUMMIT THERAPEU/S earned a news impact score of 2.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future.
Who are some of SUMMIT THERAPEU/S's key competitors?
Some companies that are related to SUMMIT THERAPEU/S include Alpine Immune Sciences (ALPN), IMMUTEP LTD/S (IMMP), Vaccinex (VCNX), Fortress Biotech (FBIO), Achaogen (AKAO), Bellerophon Therapeutics (BLPH), Sophiris Bio (SPHS), AEterna Zentaris (AEZS), Neos Therapeutics (NEOS), Arcturus Therapeutics (ARCT), Innovate Biopharmaceuticals (INNT), Merrimack Pharmaceuticals (MACK), IntelGenx Technologies (IGXT), Vistagen Therapeutics (VTGN) and Aquinox Pharmaceuticals (AQXP).
Who are SUMMIT THERAPEU/S's key executives?
SUMMIT THERAPEU/S's management team includes the folowing people:
- Mr. Glyn O. Edwards, CEO & Exec. Director (Age 62)
- Mr. Erik Ostrowski, Chief Financial Officer (Age 45)
- Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 52)
- Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 68)
- Ms. Michelle Avery, Director of Investor Relations
When did SUMMIT THERAPEU/S IPO?
(SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.
Who are SUMMIT THERAPEU/S's major shareholders?
SUMMIT THERAPEU/S's stock is owned by many different of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (3.36%) and Acadian Asset Management LLC (1.25%).
Which institutional investors are selling SUMMIT THERAPEU/S stock?
SMMT stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P..
Which institutional investors are buying SUMMIT THERAPEU/S stock?
SMMT stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC.
How do I buy shares of SUMMIT THERAPEU/S?
Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SUMMIT THERAPEU/S's stock price today?
One share of SMMT stock can currently be purchased for approximately $1.28.
How big of a company is SUMMIT THERAPEU/S?
SUMMIT THERAPEU/S has a market capitalization of $16.89 million and generates $36.07 million in revenue each year. The company earns $-9,280,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. SUMMIT THERAPEU/S employs 60 workers across the globe.
What is SUMMIT THERAPEU/S's official website?
How can I contact SUMMIT THERAPEU/S?
SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 44-0-12-3544-3939 or via email at [email protected]
MarketBeat Community Rating for SUMMIT THERAPEU/S (NASDAQ SMMT)
MarketBeat's community ratings are surveys of what our community members think about SUMMIT THERAPEU/S and other stocks. Vote "Outperform" if you believe SMMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
